JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wermeling, D. P.
Right arrow Articles by Rudy, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wermeling, D. P.
Right arrow Articles by Rudy, A. C.
Related Collections
Right arrow Pharmacology

Anesth Analg 2006;103:344-349
© 2006 International Anesthesia Research Society
doi: 10.1213/01.ane.0000226150.90317.16

ANESTHETIC PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of a New Intranasal Midazolam Formulation in Healthy Volunteers

Daniel P. Wermeling, PharmD, FASHP*, Kenneth A. Record, PharmD*, Thomas H. Kelly, PhD{dagger}, Sanford M. Archer, MD{ddagger}, Thomas Clinch§, and Anita C. Rudy, PhD§

From the *University of Kentucky College of Pharmacy; {dagger}University of Kentucky College of Medicine; {ddagger}Division of Otolaryngology – Head & Neck Surgery, University of Kentucky A. B. Chandler Medical Center; §Intranasal Therapeutics, Inc., Lexington, Kentucky.

Address correspondence and reprint requests to Daniel P. Wermeling, Pharm.D., University of Kentucky College of Pharmacy, 725 Rose Street, Lexington, Kentucky 40536. Address e-mail to dwermel{at}uky.edu.

We evaluated the pharmacokinetics and pharmacodynamics of single 5-mg doses of midazolam after administration of a novel intranasal (IN) formula, IM, and IV midazolam in an open-label, randomized, 3-way cross-over study in 12 healthy volunteers. IN doses were delivered as 0.1-mL unit-dose sprays of a novel formulation into both naris. Blood samples were taken serially from 0 to 12 h after each dose. Plasma midazolam concentrations were determined by liquid chromatography/mass spectrometry/mass spectrometry. Noncompartmental analysis was used to estimate pharmacokinetic parameters. The mean midazolam bioavailabilities and % coefficient of variation were 72.5 (12) and 93.4 (12) after the IN and IM doses, respectively. Median time to maximum concentration was 10 min for IN doses. Adverse events were minimal with all routes of administration, but nasopharyngeal irritation, eyes watering, and a bad taste were reported after IN doses. Our results support further development of this novel midazolam nasal spray.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2006 by the International Anesthesia Research Society.